CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 04/12/22

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceu...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2021 Results Conference Call March 28, 2022 04:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppen...

Cyclacel Pharmaceuticals press release (NASDAQ:CYCC): Q4 GAAP EPS of -$1.34. As of December 31, 2021, cash and cash equivalents totaled $36.6 million, compared to $33.4 million as of December 31, 2020. The Company estimates that available cash resources will fund currently planned progra...

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 – -Cash Runway to Mid 2023- -Conference Call Scheduled for March 28, 2022, at 4:30 p.m. EDT- BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSW...

CYCC, DNA, EGLX, EYEN, HNRG, IONQ, LIDR, MBII, PLAY, OTCQX:PLNHF, PROG, RSLS, THMO, WYY, XOS, ZEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close

Cyclacel Pharmaceuticals (NASDAQ:CYCC) is scheduled to announce Q4 earnings results on Friday, March 25th, after market close. The consensus EPS Estimate is -$0.71 (+74.1% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 d...

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2021 fin...

BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will be presen...

BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in...

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch Two Registration-Directed Studies for Diffe...